TY - JOUR
T1 - Identification of 5-(Aryl/Heteroaryl)amino-4-quinolones as Potent Membrane-Disrupting Agents to Combat Antibiotic-Resistant Gram-Positive Bacteria
AU - Schultz, John
AU - Costa, Stephen K.
AU - Jachak, Gorakhnath R.
AU - Hegde, Pooja V
AU - Zimmerman, Matthew
AU - Pan, Yan
AU - Josten, Michaele
AU - Ejeh, Chinedu
AU - Hammerstad, Travis
AU - Sahl, Hans Georg
AU - Pereira, Pedro M.
AU - Pinho, Mariana G.
AU - Dartois, Véronique
AU - Cheung, Ambrose
AU - Aldrich, Courtney C.
N1 - Publisher Copyright:
© 2022 American Chemical Society. All rights reserved.
PY - 2022/10/27
Y1 - 2022/10/27
N2 - Nosocomial infections caused by resistant Gram-positive organisms are on the rise, presumably due to a combination of factors including prolonged hospital exposure, increased use of invasive procedures, and pervasive antibiotic therapy. Although antibiotic stewardship and infection control measures are helpful, newer agents against multidrug-resistant (MDR) Gram-positive bacteria are urgently needed. Here, we describe our efforts that led to the identification of 5-amino-4-quinolone 111 with exceptionally potent Gram-positive activity with minimum inhibitory concentrations (MICs) ≤0.06 μg/mL against numerous clinical isolates. Preliminary mechanism of action and resistance studies demonstrate that the 5-amino-4-quinolones are bacteriostatic, do not select for resistance, and selectively disrupt bacterial membranes. While the precise molecular mechanism has not been elucidated, the lead compound is nontoxic displaying a therapeutic index greater than 500, is devoid of hemolytic activity, and has attractive physicochemical properties (clog »P = 3.8, molecular weight (MW) = 441) that warrant further investigation of this promising antibacterial scaffold for the treatment of Gram-positive infections.
AB - Nosocomial infections caused by resistant Gram-positive organisms are on the rise, presumably due to a combination of factors including prolonged hospital exposure, increased use of invasive procedures, and pervasive antibiotic therapy. Although antibiotic stewardship and infection control measures are helpful, newer agents against multidrug-resistant (MDR) Gram-positive bacteria are urgently needed. Here, we describe our efforts that led to the identification of 5-amino-4-quinolone 111 with exceptionally potent Gram-positive activity with minimum inhibitory concentrations (MICs) ≤0.06 μg/mL against numerous clinical isolates. Preliminary mechanism of action and resistance studies demonstrate that the 5-amino-4-quinolones are bacteriostatic, do not select for resistance, and selectively disrupt bacterial membranes. While the precise molecular mechanism has not been elucidated, the lead compound is nontoxic displaying a therapeutic index greater than 500, is devoid of hemolytic activity, and has attractive physicochemical properties (clog »P = 3.8, molecular weight (MW) = 441) that warrant further investigation of this promising antibacterial scaffold for the treatment of Gram-positive infections.
UR - http://www.scopus.com/inward/record.url?scp=85140856525&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140856525&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.2c01151
DO - 10.1021/acs.jmedchem.2c01151
M3 - Article
C2 - 36219779
AN - SCOPUS:85140856525
SN - 0022-2623
VL - 65
SP - 13910
EP - 13934
JO - Journal of medicinal chemistry
JF - Journal of medicinal chemistry
IS - 20
ER -